2016 Press Releases


Keyword Search
2018 | 2017 | 2016 | 2015
DateTitle 
12/13/16Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to IsraelPrinter Friendly Version
11/21/16Tocagen Presents Updated Clinical and Preclinical Data at Scientific MeetingsPrinter Friendly Version
11/10/16Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific MeetingsPrinter Friendly Version
11/02/16Tocagen Strengthens Leadership Team: Martin Duvall Appointed as Chief Executive OfficerPrinter Friendly Version
10/05/16Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy Printer Friendly Version
09/30/16Tocagen to Present Clinical and Preclinical Data at Two Scientific MeetingsPrinter Friendly Version
09/22/16First Patient Enrolled in Toca 6, Tocagen’s Trial for Metastatic Cancers Evaluating Intravenously Delivered Toca 511 VirusPrinter Friendly Version
07/06/16RiboMed and Tocagen Announce Collaboration to Analyze Epigenetic Prognostic MarkersPrinter Friendly Version
06/01/16Study Published in Science Translational Medicine Reports Favorable Safety and Extended Survival for Brain Cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene TherapyPrinter Friendly Version
05/26/16Tocagen Announces Presentations at the 2016 BIO International Convention and Boston CEO ConferencePrinter Friendly Version
05/13/16Tocagen to Present Clinical and Preclinical Data at Three Scientific MeetingsPrinter Friendly Version
05/03/16Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific MeetingPrinter Friendly Version
04/19/16Tocagen Presents Positive Preclinical, Proof-of-Mechanism Data at the American Association for Cancer Research (AACR) Annual Meeting Printer Friendly Version
04/13/16Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific ConferencesPrinter Friendly Version
03/17/16Tocagen to Present at Three Oncology ConferencesPrinter Friendly Version
03/08/16Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer to CanadaPrinter Friendly Version
02/16/16Tocagen Appoints John Wood as Vice President, Regulatory Affairs and Quality AssurancePrinter Friendly Version